ArticleFrontiers in endocrinology2025
The hemoglobin glycation index stratifies heart failure phenotypes and in-hospital risk.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association Between Hemoglobin Glycation Index and Mortality in Critically Ill Patients With Atrial Fibrillation: A Retrospective Cohort Study.Clinical cardiology · 2026Article
- Association between hemoglobin glycation index and all-cause mortality in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.Frontiers in endocrinology · 2026Article
- The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the association between the hemoglobin glycation index (HGI) and ejection fraction (EF) categories in hospitalized heart failure (HF) patients and to investigate the relationship between HGI and in-hospital worsening heart failure (WHF). Methods: This single-center retrospective study included 647 HF patients (261 HFrEF, 186 HFmrEF, 200 HFpEF). HGI was calculated as measured HbA1c minus predicted HbA1c (derived from fasting plasma glucose regression). Ordinal multinomial logistic regression and binomial logistic regression were used to evaluate the relationships between HGI (exposure) and EF-based phenotypes and in-hospital WHF (outcome), respectively, with stepwise adjustment for confounding factors. Dose-response relationships were assessed using restricted cubic spline (RCS) analysis. Results: HFrEF patients exhibited the highest HGIs and the highest incidence of In-hospital WHF (33.72% vs. 18.82% [HFmrEF] and 14.00% [HFpEF]; P < 0.001). After full adjustment, a higher HGI was significantly associated with the HFrEF phenotype. For every 1-unit increase in HGI, the probability of being classified into a higher EF category (HFrEF → HFmrEF/HFpEF) decreased by approximately 25% (OR = 0.746, 95% CI 0.617-0.902; P = 0.003; P for trend = 0.029). Regarding outcomes, HGI showed a stable, positive association with In-hospital WHF. After full adjustment, every 1-unit increase in HGI increased the risk of In-hospital WHF 2.16-fold (OR = 2.161, 95% CI 1.680-2.840; P<0.001). When divided into quartiles (Q1 as reference), the ORs for In-hospital WHF in Q2, Q3, and Q4 were 2.790, 3.811, and 7.322, respectively (P for trend < 0.001). RCS analysis revealed an approximately linear dose-response relationship. Conclusion: In hospitalized HF patients, a higher HGI was significantly associated with the HFrEF phenotype and an increased risk of in-hospital WHF. HGI may serve as a potential supplementary indicator for phenotype characterization and risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.